APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Inhibitory Polypeptide Receptor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastric Inhibitory Polypeptide Receptor Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchGastric Inhibitory Polypeptide Receptor Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Inhibitory Polypeptide Receptor Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Gastric Inhibitory Polypeptide Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Inhibitory Polypeptide Receptor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Inhibitory Polypeptide Receptor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gastric Inhibitory Polypeptide Receptor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastric Inhibitory Polypeptide Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastric Inhibitory Polypeptide Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastric Inhibitory Polypeptide Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastric Inhibitory Polypeptide Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastric Inhibitory Polypeptide Receptor market include Sanofi, Novo Nordisk A/S, AstraZeneca Plc, Zealand Pharma A/S, Longevity Biotech, Inc, Diabetica Limited, Carmot Therapeutics, Inc. and Alchemia Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastric Inhibitory Polypeptide Receptor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastric Inhibitory Polypeptide Receptor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastric Inhibitory Polypeptide Receptor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastric Inhibitory Polypeptide Receptor market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastric Inhibitory Polypeptide Receptor Segment by Company

Sanofi

Novo Nordisk A/S

AstraZeneca Plc

Zealand Pharma A/S

Longevity Biotech, Inc

Diabetica Limited

Carmot Therapeutics, Inc.

Alchemia Limited

Gastric Inhibitory Polypeptide Receptor Segment by Type

HM-15211

LBT-6030

LY-3298176

NNC-92041706

Others

Gastric Inhibitory Polypeptide Receptor Segment by Application

Obesity

Metabolic Disorder

Type 2 Diabetes

Others

Gastric Inhibitory Polypeptide Receptor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastric Inhibitory Polypeptide Receptor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastric Inhibitory Polypeptide Receptor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastric Inhibitory Polypeptide Receptor significant trends, drivers, influence factors in global and regions.

6. To analyze Gastric Inhibitory Polypeptide Receptor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Inhibitory Polypeptide Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Inhibitory Polypeptide Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Inhibitory Polypeptide Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastric Inhibitory Polypeptide Receptor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Inhibitory Polypeptide Receptor industry.

Chapter 3: Detailed analysis of Gastric Inhibitory Polypeptide Receptor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastric Inhibitory Polypeptide Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastric Inhibitory Polypeptide Receptor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastric Inhibitory Polypeptide Receptor Industry Trends Table 2. Gastric Inhibitory Polypeptide Receptor Industry Drivers Table 3. Gastric Inhibitory Polypeptide Receptor Industry Opportunities and Challenges Table 4. Gastric Inhibitory Polypeptide Receptor Industry Restraints Table 5. Global Gastric Inhibitory Polypeptide Receptor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastric Inhibitory Polypeptide Receptor Revenue Share by Company (2021-2026) Table 7. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Company (k units) & (2021-2026) Table 8. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Company (2021-2026) Table 9. Global Gastric Inhibitory Polypeptide Receptor Average Price (US$/unit) of Company (2021-2026) Table 10. Global Gastric Inhibitory Polypeptide Receptor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastric Inhibitory Polypeptide Receptor Key Company Manufacturing Base & Headquarters Table 12. Global Gastric Inhibitory Polypeptide Receptor Company, Product Type & Application Table 13. Global Gastric Inhibitory Polypeptide Receptor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastric Inhibitory Polypeptide Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of HM-15211 Table 18. Significant Companies of LBT-6030 Table 19. Significant Companies of LY-3298176 Table 20. Significant Companies of NNC-92041706 Table 21. Significant Companies of Others Table 22. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type (2021-2026) & (k units) Table 24. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type (2027-2032) & (k units) Table 25. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Type (2021-2026) Table 26. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Type (2027-2032) Table 27. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type (2021-2026) Table 31. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Obesity Table 33. Significant Companies of Metabolic Disorder Table 34. Significant Companies of Type 2 Diabetes Table 35. Significant Companies of Others Table 36. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application (2021-2026) & (k units) Table 38. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application (2027-2032) & (k units) Table 39. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Application (2021-2026) Table 40. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Application (2027-2032) Table 41. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application (2021-2026) Table 45. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application (2027-2032) Table 46. Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2026) & (k units) Table 48. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2021-2026) Table 49. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2027-2032) & (k units) Table 50. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2027-2032) Table 51. Global Gastric Inhibitory Polypeptide Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Region (2021-2026) Table 54. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Region (2027-2032) Table 56. Global Gastric Inhibitory Polypeptide Receptor Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Gastric Inhibitory Polypeptide Receptor Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Gastric Inhibitory Polypeptide Receptor Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (k units) Table 61. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2021-2026) Table 62. Global Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032) & (k units) Table 63. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2027-2032) Table 64. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Gastric Inhibitory Polypeptide Receptor Sales Value Market Share by Country (2021-2026) Table 66. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Gastric Inhibitory Polypeptide Receptor Sales Value Market Share by Country (2027-2032) Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sanofi Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 72. Sanofi Recent Development Table 73. Novo Nordisk A/S Company Information Table 74. Novo Nordisk A/S Business Overview Table 75. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 77. Novo Nordisk A/S Recent Development Table 78. AstraZeneca Plc Company Information Table 79. AstraZeneca Plc Business Overview Table 80. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 82. AstraZeneca Plc Recent Development Table 83. Zealand Pharma A/S Company Information Table 84. Zealand Pharma A/S Business Overview Table 85. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 87. Zealand Pharma A/S Recent Development Table 88. Longevity Biotech, Inc Company Information Table 89. Longevity Biotech, Inc Business Overview Table 90. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 92. Longevity Biotech, Inc Recent Development Table 93. Diabetica Limited Company Information Table 94. Diabetica Limited Business Overview Table 95. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 97. Diabetica Limited Recent Development Table 98. Carmot Therapeutics, Inc. Company Information Table 99. Carmot Therapeutics, Inc. Business Overview Table 100. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 102. Carmot Therapeutics, Inc. Recent Development Table 103. Alchemia Limited Company Information Table 104. Alchemia Limited Business Overview Table 105. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 107. Alchemia Limited Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Gastric Inhibitory Polypeptide Receptor Distributors List Table 111. Gastric Inhibitory Polypeptide Receptor Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Gastric Inhibitory Polypeptide Receptor Product Image Figure 2. Global Gastric Inhibitory Polypeptide Receptor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastric Inhibitory Polypeptide Receptor Sales (2021-2032) & (k units) Figure 5. Global Gastric Inhibitory Polypeptide Receptor Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Gastric Inhibitory Polypeptide Receptor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. HM-15211 Image Figure 10. LBT-6030 Image Figure 11. LY-3298176 Image Figure 12. NNC-92041706 Image Figure 13. Others Image Figure 14. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Type (2021-2032) Figure 17. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type (2021-2032) Figure 20. Obesity Image Figure 21. Metabolic Disorder Image Figure 22. Type 2 Diabetes Image Figure 23. Others Image Figure 24. Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Application (2021-2032) Figure 27. Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application (2021-2032) Figure 30. Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Gastric Inhibitory Polypeptide Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 35. North America Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 41. South America Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Gastric Inhibitory Polypeptide Receptor Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Gastric Inhibitory Polypeptide Receptor Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • HM-15211
  • LBT-6030
  • LY-3298176
  • NNC-92041706
  • Others
Applications
  • Obesity
  • Metabolic Disorder
  • Type 2 Diabetes
  • Others
Companies covered
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca Plc
  • Zealand Pharma A/S
  • Longevity Biotech, Inc
  • Diabetica Limited
  • Carmot Therapeutics, Inc.
  • Alchemia Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  4. 1.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales Volume (2021-2032)
  5. 1.2.3 Global Gastric Inhibitory Polypeptide Receptor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastric Inhibitory Polypeptide Receptor Market Dynamics
  1. 2.1 Gastric Inhibitory Polypeptide Receptor Industry Trends
  2. 2.2 Gastric Inhibitory Polypeptide Receptor Industry Drivers
  3. 2.3 Gastric Inhibitory Polypeptide Receptor Industry Opportunities and Challenges
  4. 2.4 Gastric Inhibitory Polypeptide Receptor Industry Restraints
3 Gastric Inhibitory Polypeptide Receptor Market by Company
  1. 3.1 Global Gastric Inhibitory Polypeptide Receptor Company Revenue Ranking in 2025
  2. 3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Company (2021-2026)
  3. 3.3 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastric Inhibitory Polypeptide Receptor Average Price by Company (2021-2026)
  5. 3.5 Global Gastric Inhibitory Polypeptide Receptor Company Ranking (2024-2026)
  6. 3.6 Global Gastric Inhibitory Polypeptide Receptor Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastric Inhibitory Polypeptide Receptor Company Product Type and Application
  8. 3.8 Global Gastric Inhibitory Polypeptide Receptor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastric Inhibitory Polypeptide Receptor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastric Inhibitory Polypeptide Receptor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastric Inhibitory Polypeptide Receptor Market by Type
  1. 4.1 Gastric Inhibitory Polypeptide Receptor Type Introduction
  2. 4.1.1 HM-15211
  3. 4.1.2 LBT-6030
  4. 4.1.3 LY-3298176
  5. 4.1.4 NNC-92041706
  6. 4.1.5 Others
  7. 4.2 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type
  8. 4.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type
  12. 4.3.1 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Type (2021-2032)
  14. 4.3.3 Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type (2021-2032)
5 Gastric Inhibitory Polypeptide Receptor Market by Application
  1. 5.1 Gastric Inhibitory Polypeptide Receptor Application Introduction
  2. 5.1.1 Obesity
  3. 5.1.2 Metabolic Disorder
  4. 5.1.3 Type 2 Diabetes
  5. 5.1.4 Others
  6. 5.2 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application
  7. 5.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Gastric Inhibitory Polypeptide Receptor Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application
  11. 5.3.1 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Application (2021-2032)
  13. 5.3.3 Global Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application (2021-2032)
6 Gastric Inhibitory Polypeptide Receptor Regional Sales and Value Analysis
  1. 6.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2032)
  3. 6.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021-2026
  4. 6.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2027-2032)
  5. 6.3 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Region (2027-2032)
  9. 6.5 Global Gastric Inhibitory Polypeptide Receptor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  12. 6.6.2 North America Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  15. 6.7.2 Europe Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  21. 6.9.2 South America Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Value Share by Country, 2025 VS 2032
7 Gastric Inhibitory Polypeptide Receptor Country-level Sales and Value Analysis
  1. 7.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
  4. 7.3.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026)
  5. 7.3.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032)
  6. 7.4 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastric Inhibitory Polypeptide Receptor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastric Inhibitory Polypeptide Receptor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Gastric Inhibitory Polypeptide Receptor Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novo Nordisk A/S
  8. 8.2.1 Novo Nordisk A/S Company Information
  9. 8.2.2 Novo Nordisk A/S Business Overview
  10. 8.2.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
  12. 8.2.5 Novo Nordisk A/S Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Zealand Pharma A/S
  20. 8.4.1 Zealand Pharma A/S Company Information
  21. 8.4.2 Zealand Pharma A/S Business Overview
  22. 8.4.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
  24. 8.4.5 Zealand Pharma A/S Recent Developments
  25. 8.5 Longevity Biotech, Inc
  26. 8.5.1 Longevity Biotech, Inc Company Information
  27. 8.5.2 Longevity Biotech, Inc Business Overview
  28. 8.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Portfolio
  30. 8.5.5 Longevity Biotech, Inc Recent Developments
  31. 8.6 Diabetica Limited
  32. 8.6.1 Diabetica Limited Company Information
  33. 8.6.2 Diabetica Limited Business Overview
  34. 8.6.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
  36. 8.6.5 Diabetica Limited Recent Developments
  37. 8.7 Carmot Therapeutics, Inc.
  38. 8.7.1 Carmot Therapeutics, Inc. Company Information
  39. 8.7.2 Carmot Therapeutics, Inc. Business Overview
  40. 8.7.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Portfolio
  42. 8.7.5 Carmot Therapeutics, Inc. Recent Developments
  43. 8.8 Alchemia Limited
  44. 8.8.1 Alchemia Limited Company Information
  45. 8.8.2 Alchemia Limited Business Overview
  46. 8.8.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
  48. 8.8.5 Alchemia Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastric Inhibitory Polypeptide Receptor Value Chain Analysis
  2. 9.1.1 Gastric Inhibitory Polypeptide Receptor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastric Inhibitory Polypeptide Receptor Sales Mode & Process
  6. 9.2 Gastric Inhibitory Polypeptide Receptor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastric Inhibitory Polypeptide Receptor Distributors
  9. 9.2.3 Gastric Inhibitory Polypeptide Receptor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst